Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 4/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14411413 | 1.00 | FSCN1 (0.38) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL5451774 | 1.00 | FSCN1 (0.38) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL5454298 | 0.96 | FSCN1 (0.39) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL5454301 | 0.96 | FSCN1 (0.39) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL14411412 | 0.96 | FSCN1 (0.39) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL14411410 | 0.96 | FSCN1 (0.37) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL5448797 | 0.96 | FSCN1 (0.37) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL5448794 | 0.96 | FSCN1 (0.37) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL14412201 | 0.95 | PDE10A (0.40) | FSCN1CCR3CNR1WDR5CNR2 | |
| SCHEMBL14411406 | 0.95 | PPARG (0.37) | FSCN1CCR3CNR1WDR5CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | FSCN1 4090/4885CCR3 1400/4885CNR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.